A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

March 24, 2023

Study Completion Date

April 21, 2023

Conditions
DyslipidemiaHypercholesterolemiaHigh Cholesterol
Interventions
DRUG

Obicetrapib

tablet

DRUG

Placebo

No active ingredient

Trial Locations (10)

Unknown

Nippon Kokan Fukuyama Hospital, Fukuyama

Nakamura Cardiology and Cardiovascular Surgery Clinic, Itoshima

Kishiwada Tokushu-Kai Hospital, Osaka

Kyosokai AMC NISHI-UMEDA Clinic, Osaka

Sakurabashi Watanabe Hospital, Osaka

Uji Tokushu-Kai Hospital, Osaka

Sanai Hospital, Saitama

Shinden Higashi Clinic, Sendai

Soka-Sugiura Clinic, Sōka

Sugiura Clinic, Tokyo

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY

NCT05421078 - A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | Biotech Hunter | Biotech Hunter